Clovis Oncology Reaches Analyst Target Price
October 11, 2016 at 09:30 AM EDT
In recent trading, shares of Clovis Oncology Inc (CLVS) have crossed above the average analyst 12-month target price of $31.83, changing hands for $32.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..